daclizumab

Type: Product
Name: daclizumab
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

ACTRIMS/ECTRIMS Summary

17 September 2014Author:A review of some of the research from the recent ACTRIMS / ECTRIMS conference, including daclizumab, generic glatiramer acetate, a fingolimod similar, body temperature, cholesterol, comorbidities, stem cells, cognition, genetics, ... [Published Multiple Sclerosis Trust - Sep 18 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Regeneron's Eylea scores Breakthrough label

Keytruda was the first of the new PD-1 class of immuno-oncology drugs to reach the US, but Bristol-Myers Squibb and Ono could run away with the competition, according to one ...Analysts do not expect odanacatib to be a major earner.Phase-III results of ... [Published Medical Marketing And Media - Sep 17 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

ECTRIMS 2014: Daclizumab results

Daclizumab was my number 1 ECTRIMS highlight: what is it telling us about MS?  #MSBlog #MSResearch "My number one ECTRIMS highlight is the MRI daclizumab results, which shows that daclizumab reduces brain atrophy compared to Avonex in both year 1 and ... [Published Multiple Sclerosis Research - Sep 17 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 1 reports

Daclizumab HYP a new kid on the block

Othman AA, Tran JQ, Tang MT, Dutta S. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers: Integrated Analysis of Intravenous and Subcutaneous, Single- and Multiple-Dose Administration.  Clin Pharmacokinet. 2014 Sep 12. ... [Published Multiple Sclerosis Research - Sep 16 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

East Coast Biotech Roundup: Maraganore, Flex, NPS, Retrophin, & More

It’s back to work, back to school, and back to the grind in biotech. One local company inched towards a potential FDA approval, yet its stock is down more than 10 percent. Another biotech came under fire for a big price hike on an old drug. And a new ... [Published Xconomy - Sep 15 2014]
First reported Sep 14 2014 - Updated Sep 14 2014 - 1 reports

EBV and HHV-6 reactive cells concentrated in the CNS

Is MS caused by a virus? T cells reactive againts HHV-6 and EBV may provide a clue. #MSBlog #MSResearch "The study below suggests that T cells responding to specific herpes viruses are enriched in the spinal fluid of MSers and not T cells responding ... [Published Multiple Sclerosis Research - Sep 14 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 4 reports

AbbVie and Biogen inch toward the FDA with once-a-month MS drug

Partners Biogen Idec ($BIIB) and AbbVie ($ABBV) are touting late-stage results for their new, monthly multiple sclerosis treatment, preparing to hand in regulatory applications next year and contend in a crowded market.The drug, daclizumab, is a subcutaneous ... [Published FierceBiotech - Sep 12 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Novel Drug Beats Avonex for MS Efficacy; Safety Still a Worry

BOSTON (MedPage Today) -- Daclizumab HYP cut relapse rates and disability progression in multiple sclerosis patients more effectively than interferon beta-1a (Avonex) in a phase III trial, but liver toxicity with the IL-2 inhibitor reared its head ag ... [Published MedPageToday.com - medical news plus CME for ph ... - Sep 12 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

5 Things Biogen Idec Inc's Management Wants You to Know

Biogen Idec ( NASDAQ: BIIB     ) held a conference call to go along with the release of second quarter earnings. Here are five things that management said on the call about Biogen Idec's ongoing prospects (quotes courtesy of S&P Capital IQ ).George ... [Published Motley Fool Discussion Boards - Sep 03 2014]
First reported Aug 24 2014 - Updated Aug 24 2014 - 1 reports

Hangout with us at ECTRIMS

Following on from the success of our previous public engagement activity MS Question Time , at the joint ACTRIMS-ECTRIMS conference this year in Boston we are holding three ‘Question Time Hangouts’. The ACTRIMS-ECTRIMS meeting is an important date ... [Published Multiple Sclerosis Research - Aug 24 2014]
First reported Aug 24 2014 - Updated Aug 24 2014 - 1 reports

Politics: drug pricing

Do Pharma CEOs' deserve their large bonuses? #MSBlog #MSResearch "Do MS DMTs justify their current premium? A large number of MS drugs are repurposed and hence their risk of failure has been low. Despite this the costs remain high.""Re-purposed licensed ... [Published Multiple Sclerosis Research - Aug 24 2014]
First reported Jun 16 2014 - Updated Jun 17 2014 - 4 reports

Another eagle has landed: phase 3 daclizumab trial is positive

Daclizumab: another repurposed drug resurfaces as a treatment for MS #MSBlog #MSResearch Press Release Biogen-Idec and Abbvie have announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority ... [Published Multiple Sclerosis Research - Jun 16 2014]

Quotes

"The obvious conclusion of the Maria-Pia Sormani meta-analysis is that if you want to tackle MS head on and treat-2-target of NEDA and prevent end-organ damage you need to be on very high efficacy drugs. The pressing question is can you identify MSers who don't need this aggressive approach? I suspect you can but we will need to incorporate routine brain atrophy measurements into clinical practice. At the moment due to issues of measurement variability and factors that cause short-term fluctuations in brain volume we can't implement this routinely in clinical practice. However, as I say this I am aware of about 5 MS centres in the world that use brain atrophy in clinical practice. One of these centres is in Prague and when I visited the centre earlier this year I was impressed by the power of their technology. It also made me realise that without brain atrophy measurements some of the less effective therapies are creating a false sense of security. I saw several serial brain MRI series of patients with NEDA (no evident disease activity) that had remarkable brain volume loss over 6-8 years of follow-up. These patients must have ongoing MS activity beneath the surface and are acquiring damage that is not clinically apparent. In other words  the shredder is chewing up their reserve capacity and it is only a matter of time before they present with clinically overt SPMS. As we now have drugs that slow down brain atrophy rates these patients may be eligible for these treatments. Unfortunately, we don't have the evidence that escalating treatment based purely on brain atrophy will be effective or not.  What we need is a clinical trial to test this hypothesis."
"The results from DECIDE further support the potential of ZINBRYTA and we look forward to submitting the data for this investigational therapy to regulatory agencies" said Michael Severino, M D , executive vice president, Research and Development and chief scientific officer, AbbVie
...We simply can't ignore Daclizumab's putative mode of action; it is telling us something very important about MS. "The great tragedy of science - the slaying of a beautiful hypothesis by an ugly fact."  Thomas Huxley
Is MS caused by a virus? T cells reactive againts HHV-6 and EBV may provide a clue. #MSBlog #MSResearch "The study below suggests that T cells responding to specific herpes viruses are enriched in the spinal fluid of MSers and not T cells responding to brain proteins or antigens. This is fascinating and suggests that the herpes viruses HHV-6 and EBV, but not CMV, are involved in the pathogenesis of MS. T cells are the immune cells responsible for orchestrating memory immune responses and are hence very important read-outs of what is happening in the brains and spinal cords of MSers. The fact that an effective MS treatment such as Daclizumab reverses these T cell responses indicates that they may be important in MS and a marker of disease activity. History may judge this paper as being very important, once we pin down the cause of MS we may be able to use the methods described in this paper to prove causation. This paper clearly supports the viral hypothesis of MS."

More Content

All (48) | News (21) | Reports (0) | Blogs (27) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
ClinicSpeak: MS phenotypes by MRI [Published Multiple Sclerosis Research - 4 hours ago]
Biogen Idec Announces Strides In Clinical Studi... [Published Bioresearch Online - Sep 18 2014]
ACTRIMS/ECTRIMS Summary [Published Multiple Sclerosis Trust - Sep 18 2014]
Biogen and AbbVie report reduced disease activi... [Published Pharma Letter - Sep 18 2014]
Biogen Idec and AbbVie Issues Phase 3 Decide St... [Published Individual.com - Sep 17 2014]
ECTRIMS 2014: Daclizumab results [Published Multiple Sclerosis Research - Sep 17 2014]
Regeneron's Eylea scores Breakthrough label [Published Medical Marketing And Media - Sep 17 2014]
Daclizumab HYP a new kid on the block [Published Multiple Sclerosis Research - Sep 16 2014]
AbbVie, Biogen to file MS drug next year [Published Medical Marketing And Media - Sep 16 2014]
Biogen/AbbVie Report Positive Data on MS Drug Z... [Published Yahoo! Finance - Sep 15 2014]
East Coast Biotech Roundup: Maraganore, Flex, N... [Published Xconomy - Sep 15 2014]
EBV and HHV-6 reactive cells concentrated in th... [Published Multiple Sclerosis Research - Sep 14 2014]
AbbVie, Biogen Announce Positive Phase III Resu... [Published Bidness Etc - Sep 12 2014]
Biogen Reports Positive Two-Year Data on MS Dru... [Published Zacks.com - Sep 12 2014]
AbbVie and Biogen inch toward the FDA with once... [Published FierceBiotech - Sep 12 2014]
Novel Drug Beats Avonex for MS Efficacy; Safety... [Published MedPageToday.com - medical news plus CME for ph ... - Sep 12 2014]
Detailed Results from Biogen Idec and AbbVie’s ... [Published Business Wire Photo/Multimedia News - Sep 12 2014]
Detailed Results from Biogen Idec and AbbVie’s ... [Published Business Wire News with Multimedia - Sep 12 2014]
Detailed Results from Biogen Idec and AbbVie’s ... [Published Business Wire Health News - Sep 12 2014]
5 Things Biogen Idec Inc's Management Wants You... [Published Motley Fool Discussion Boards - Sep 03 2014]
Company Update: Biogen Idec Inc (NASDAQ:BIIB) –... [Published Jutia Group - Aug 26 2014]
Hangout with us at ECTRIMS [Published Multiple Sclerosis Research - Aug 24 2014]
Politics: drug pricing [Published Multiple Sclerosis Research - Aug 24 2014]
Company Update: Biogen Idec Inc (NASDAQ:BIIB) –... [Published Jutia Group - Aug 21 2014]
Biogen Strengthens MS Portfolio with Plegridy F... [Published Nasdaq - Aug 19 2014]
Biogen Strengthens MS Portfolio with Plegridy F... [Published Zacks.com - Aug 19 2014]
FDA approves Biogen Idec's long-acting MS therapy [Published PMLive - Aug 18 2014]
NK cells are they important in MS [Published Multiple Sclerosis Research - Aug 18 2014]
Market Update: Biogen Idec Inc (NASDAQ:BIIB) – ... [Published Jutia Group - Aug 16 2014]
MSology at ACTRIMS-ECTRIMS – BOSTON 2014 [Published MSology - Aug 14 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
ClinicSpeak: MS phenotypes by MRI [Published Multiple Sclerosis Research - 4 hours ago]
Brain atrophy is ready for prime time: MRIologists need to sort-out the technology. #ClinicSpeak #MSBlog #MSResearch "The study below divides MSers into four categories based on two MRI metrics; (1) high or low T2 volumes, an integrator of focal inflammation ...
ECTRIMS 2014: Daclizumab results [Published Multiple Sclerosis Research - Sep 17 2014]
Daclizumab was my number 1 ECTRIMS highlight: what is it telling us about MS?  #MSBlog #MSResearch "My number one ECTRIMS highlight is the MRI daclizumab results, which shows that daclizumab reduces brain atrophy compared to Avonex in both year 1 and ...
Daclizumab HYP a new kid on the block [Published Multiple Sclerosis Research - Sep 16 2014]
Othman AA, Tran JQ, Tang MT, Dutta S. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers: Integrated Analysis of Intravenous and Subcutaneous, Single- and Multiple-Dose Administration.  Clin Pharmacokinet. 2014 Sep 12. ...
EBV and HHV-6 reactive cells concentrated in th... [Published Multiple Sclerosis Research - Sep 14 2014]
Is MS caused by a virus? T cells reactive againts HHV-6 and EBV may provide a clue. #MSBlog #MSResearch "The study below suggests that T cells responding to specific herpes viruses are enriched in the spinal fluid of MSers and not T cells responding ...
Novel Drug Beats Avonex for MS Efficacy; Safety... [Published MedPageToday.com - medical news plus CME for ph ... - Sep 12 2014]
BOSTON (MedPage Today) -- Daclizumab HYP cut relapse rates and disability progression in multiple sclerosis patients more effectively than interferon beta-1a (Avonex) in a phase III trial, but liver toxicity with the IL-2 inhibitor reared its head ag ...
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.